Subtype
Gastroesophageal Junction Adenocarcinoma
CI-CAN-00005403Explore in graph →
228 active trials9 approved drugs25 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005403Explore in graph →
Clinical trials
695 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (82)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06251973 | A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer | active not recruiting | Phase 2 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07432295 | Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) | recruiting | Phase 2 | 180 | I-Mab Biopharma US LimitedINDUSTRY | 3 | May 14, 2026 |
| clinicaltrials |
| NCT06862479 | Luso-Cor Stent Compared to Other Endoscopic Techniques for Management of Fistulas and Anastomotic Dehiscences(ES-LCCE-UDFM)(ES-LCCE-UDFM) | enrolling by invitation | — | 180 | Unidade Local de Saúde Santa MariaOTHER_GOV | 1 | May 6, 2026 | clinicaltrials |
| NCT04034251 | Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis | terminated | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | May 5, 2026 | clinicaltrials |
| NCT04511039 | Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer | recruiting | Phase 1 | 45 | Roswell Park Cancer InstituteOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05076279 | Safety and Efficacy of Single or Reduced Ports Laparoscopic Gastrectomy for Advanced Gastric Cancer (SPACE-01) | active not recruiting | N/A | 108 | Seoul National University Bundang HospitalOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07007182 | Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer | recruiting | Phase 2 | 54 | Jinbo YueOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07178808 | PHASE II EVALUATION OF CYTOREDUCTION SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS/HIPEC) IN GASTRIC CANCER | recruiting | Phase 2 | 30 | Banner HealthOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06846346 | Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma(GRACIE) | recruiting | Phase 2 | 88 | UNICANCEROTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07551362 | Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer(DUET-GEJ) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07551466 | AI Model for Early Gastric Cancer Diagnosis Using Endoscopic Imaging(XAI-EGC) | recruiting | — | 100 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07353684 | Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer | recruiting | Phase 2 | 49 | Beijing Friendship HospitalOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05480384 | Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction | active not recruiting | Phase 2 | 1 | Brown UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07040059 | A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | terminated | Phase 1 / Phase 2 | 2 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07223424 | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy(PSI-Immune) | recruiting | Phase 2 | 880 | Diwakar DavarOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07533825 | Laparoscopic Staging for Stage III Gastric Cancer(CGCA202501) | enrolling by invitation | N/A | 968 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03161522 | Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer | recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04220827 | Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer | active not recruiting | Phase 1 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02606396 | Cryotherapy for Malignant Dysphagia in Patients With Advanced Esophageal Cancer | completed | N/A | 15 | Hunter Holmes Mcguire Veteran Affairs Medical CenterFED | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07529613 | Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma(T-DXd_HER2Low) | completed | Phase 1 / Phase 2 | 30 | National Cancer Center Hospital EastOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT05745857 | Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas(SLURP) | recruiting | Phase 2 | 25 | University Medical Center GroningenOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05567835 | A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer(TOGAR) | terminated | Phase 2 | 3 | Baylor College of MedicineOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05927857 | Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer . | recruiting | Phase 1 / Phase 2 | 45 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05034887 | Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma | active not recruiting | Phase 2 | 64 | National Cancer Center Hospital EastOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05753306 | Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study | recruiting | Phase 2 | 40 | Mayo ClinicOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06504615 | Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France(METAGIO) | active not recruiting | — | 208 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07507071 | Comparison of the Sensitivity of pCLE and Pathological Biopsy for Gastric Mucosal Lesions(pCLE) | not yet recruiting | — | 169 | Changhai HospitalOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07507526 | A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer(DTP-HER2) | not yet recruiting | Phase 2 | 76 | Sun Yat-sen UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05514769 | Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty Versus Esophagogastric Anastomosis for Gastric Cancer | recruiting | N/A | 60 | Nanchong Central HospitalOTHER_GOV | 1 | Mar 31, 2026 | clinicaltrials |
| NCT02366819 | Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer | suspended | Phase 4 | 36 | University of ChicagoOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07502027 | A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 4 | 55 | Huazhong University of Science and TechnologyOTHER | 0 | Mar 30, 2026 | clinicaltrials |
| NCT07490340 | Trans-Oral Sampling as an Alternative Surveillance of Barrett's Esophagus Pilot(TOSS pilot) | active not recruiting | — | 60 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT07312370 | Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing | not yet recruiting | Phase 4 | 120 | LanZhou UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT05411133 | Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients | completed | Phase 1 | 33 | Arbele Pty LtdINDUSTRY | 2 | Mar 19, 2026 | clinicaltrials |
| NCT04007744 | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 36 | Mayo ClinicOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT00587314 | The Effect of Ablation Therapy on Barrett's Esophagus(ablation IN BE) | enrolling by invitation | — | 600 | Mayo ClinicOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07453433 | Submucosal Pressure Ejection Endoscopic Dissection for Early Gastric Cancer: a Retrospective Cohort Study | completed | — | 548 | Shanghai East HospitalOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07455422 | A Study of Barrett's Esophagus Patients: Optimization of a Risk Model to Better Predict the Development of Cancer Recurrence and the Effect of Risk Profile Disclosure on Patient Quality of Life and Fear of Cancer(Endeavor-2) | not yet recruiting | N/A | 266 | University Hospital, AntwerpOTHER | 7 | Mar 6, 2026 | clinicaltrials |
| NCT04900818 | Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 330 | I-Mab Biopharma US LimitedINDUSTRY | 2 | Mar 5, 2026 | clinicaltrials |
| NCT06461910 | Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 2 | 30 | Zekuan XuOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT03686488 | TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | completed | Phase 2 | 23 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT06356311 | A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)(TroFuse-015) | active not recruiting | Phase 3 | 450 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Feb 27, 2026 | clinicaltrials |
| NCT06532006 | A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer | recruiting | Phase 3 | 550 | Shanghai Henlius BiotechINDUSTRY | 17 | Feb 27, 2026 | clinicaltrials |
| NCT07438418 | An Observational Study on Gastric Cancer in High-risk Individuals | not yet recruiting | — | 3,000 | Fudan UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06943781 | Prospective Gastric Cancer Screening Using Helicobacter Pylori High-Risk Single Nucleotide Polymorphism Detection | recruiting | — | 15,000 | Fudan UniversityOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT03997162 | Early Recovery After Surgery Protocol in Improving Quality of Life in Participants With Stage 0-IIIC Gastric Cancer Undergoing Surgery | active not recruiting | — | 52 | City of Hope Medical CenterOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT04430738 | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers | active not recruiting | Phase 2 | 40 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 2 | Feb 24, 2026 | clinicaltrials |
| NCT06523374 | A Study of Barrett's Esophagus Patients to Investigate Quality of Life and Fear of Cancer, and Optimize a Risk Model Based on Biomarkers and New Technologies to Better Predict the Development of Cancer(Endeavor-1) | recruiting | N/A | 50 | University Hospital, AntwerpOTHER | 6 | Feb 24, 2026 | clinicaltrials |
| NCT07405931 | Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients | recruiting | N/A | 414 | Ulsan University HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
Data updated 22 days agoSource updated May 15, 2026source: clinicaltrials